Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on (2R,3S) MPGM. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113174377B reveals a stable carbonyl reductase mutant for synthesizing (2R,3S)-MPGM with 100% theoretical yield, offering significant cost reduction in API manufacturing.
Patent CN113174377A reveals stable carbonyl reductase mutants for high-yield diltiazem intermediate synthesis, offering cost-effective biocatalysis solutions.